42 research outputs found
High Yields of Shrimp Oil Rich in Omega-3 and Natural Astaxanthin from Shrimp Waste
A valued marine oil rich in omega-3 lipids and natural astaxanthin is obtained with remarkably high yield (up to 5 wt %) extending to pink shrimp waste (head and carapace) using the approach to extract fish oil from fish processing byproducts using d-limonene. Biobased limonene is an excellent solvent for both unsaturated lipids and astaxanthin-based carotenoids preventing oxidative degradation during the extraction cycle including solvent separation at 85 °C. Explaining the deep red color of the shrimp oil obtained, computational simulation suggests that d-limonene is also a good solvent for natural astaxanthin abundant in shrimp
Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: A Systematic Review for Post Mortem Applications
The complement system has a significant role in myocardial ischemia/reperfusion injury,
being responsible for cell lysis and amplification of inflammatory response. In this context, several studies
highlight that terminal complement complex C5b-9, also known as the membrane attack complex
(MAC), is a significant contributor. The MAC functions were studied by many researchers analyzing
the characteristics of its activation in myocardial infarction. Here, a systematic literature review
was reported to evaluate the principal features, advantages, and limits (regarding the application)
of complement components andMAC in post mortem settings to perform the diagnosis of myocardial
ischemia/infarction. The review was performed according to specific inclusion and exclusion criteria,
and a total of 26 studies were identified. Several methods studiedMAC, and each study contributes to
defining better howandwhen it affects themyocardial damage in ischemic/reperfusion injury. The articles
were discussed, focusing on the specificity, sensibility, and post mortem stability ofMAC as a marker of
myocardial ischemia/infarction, supporting the usefulness in routine post mortem investigation
Evaluation of the Influence of MnS in Forged Steel 38MnVS6 on Fatigue Life
Manganese sulfides (MnS) are nonmetallic, ductile inclusions with high melting temperature (1610 °C) which improve the machinability and retard the grain growth in steels, in addition of contributing to avoid cracking during hot working. In this paper, the effect of manganese sulfides on the fatigue life of the vanadium micro-alloyed forging steel 38MnVS6 is discussed. Force-controlled fatigue tests are performed on small sized specimens until the crack occurs. The fatigue life of the forged material, presented by Wöhler curves, is considerably reduced at high levels of the nominal stress amplitude compared to the wrought material. Moreover, it is evident that the presence of longer and thinner particles of MnS reduces the scatter band of Wöhler curves and decreases the fatigue strength of the material. This paper presents a first attempt to find a relation between the shape and content of manganese sulfides due to the forging process and the fatigue life of the material
FIBRONECTINA: NUOVO MARKER DI DANNO UROTELIALE NELLA TERAPIA ADIUVANTE INTRAVESCICALE DEI TUMORI VESCICALI NON MUSCOLO INVASIVI
FIBRONECTIN (FN) AND UROTHELIAL DAMAGE SECONDARY TO ADJUVANT INTRAVESICAL THERAPY
Introduction and Objectives: Intravesical chemotherapy has
been proven effective in preventing recurrence of low-risk
non-muscle invasive bladder cancer (NMIBC). BCG is recognised as the best conservative treatment for intermediate
and high risk NMIBC. Maintenance for at least one year is
required to ameliorate the efficacy of adjuvant therapy.
Discomfort and toxicity often cause interruption of adjuvant
therapy, BCG particularly. Almost 50% of the patients
undergoing BCG does not complete one year. A biomarker of
urothelium damage would be helpful for timely detection of
toxicity in order to ameliorate patient’s tolerance and
compliance. The aim of the present study was to evaluate the
gene expression of Fibronectin (FN) in bladder washing in
relation with local toxicity due to adjuvant intravesical therapy.
Patients and Methods: Out of 26 asymptomatic patients
undergoing intravesical prophylaxis with mitomycin (40
mg/40 ml), epirubicin (80 mg/50 ml) or BCG Connaught (81
mg/50 ml) and 10 volunteers as control group, 62 samples of
bladder washing were collected before, during and after
therapy. The samples were analyzed by isolation of cellular
RNA using a miRNeasy Mini Kit (Qiagen®). FN gene
expression was analyzed by RT-PCR. The ΔΔCt method after
normalization with endogenous reference 18s rRNA was
adopted. An average Ct value for each RNA was obtained for
triplicate reactions. Local toxicity was classified into 3 grades:
0-1. mild (no medical therapy); 2. moderate (medical therapy);
3. severe (instillation postponed for 1-2 weeks or intravesical
solution of hyaluronic acid and chondroitin sulphate
administered). Results: FN gene expression, compared to
controls, was increased 1.1 fold after TUR and before
intravesical therapy. During therapy it remained unchanged
(1.0 fold). However it was increased 1.1 fold in absence of
local toxicity, but to a median value of 3.6 fold in presence of
severe toxicity. Particularly, the mean values, compared to
controls, were 2.4 (range: 0.3-6.1), 1.1 (range: 0.1-2.3), 9.3
(range: 0.2-45.2), before therapy, in absence and in presence
of local toxicity, respectively. Of interest, patients receiving
intravesical hyaluronic acid and chondroitin sulphate solution
showed a median FN gene expression of 0.2 fold (range 0.1-
0.7), decreasing from 3 to 0.6 and from 4 to 0.2 fold in two
patients contemporary with symptomatic relief. Discussion:
Few studies have correlated the gene expression of FN to
bladder urothelial damage, in interstitial cystitis (1). FN plays
an important role on BCG activity (2). A marker of topical
toxicity would be helpful to improve the tolerance and to
reduce the drop-out rates of intravesical therapy. The
measurement in bladder washing is a simple and direct
evaluation of urothelial FN gene activity. This method avoids
all the bias due to the evaluation of FN protein expression in
urine. The overexpression of FN gene indicates the presence
of urothelial damage and activation of repairing processes.
Normal and downexpression indicate the absence or healing
of urothelial damage. Preliminarily, our study shows a
significant correlation between FN gene expression on bladder
washing and local toxicity. Furthermore, FN seems to be
reduced by the intravesical administration of intravesical hyaluronic acid and chondroitin sulphate solution. Conclusion:
FN gene expression in bladder washing emerges as a simple
and promising marker of urothelial damage. Further and larger
studies should be justified.
Acknowledgements: We wish to thank IBSA for unrestricted grant
and the GSTU Foundation for administrative support.
1 Blalock EM et al: Gene expression analysis of urine
sediment: evaluation for potential noninvasive markers of
interstitial cystitis/bladder pain syndrome. J Urol 187: 725,
2012.
2 Eissa S et al: Diagnostic value of fibronectin and mutant p53
in the urine of patients with bladder cancer: impact on
clinicopathological features and disease recurrence 27: 1286,
2010
COMPLIANCE WITH ONE YEAR MAINTENANCE INTRAVESICAL BCG IN PATIENTS AFFECTED BY T1G3 BLADDER CANCER
Introduction: BCG maintenance for at least one year is the
best regimen for prevention of recurrence and progression in
high risk non muscle invasive bladder cancer (NMIBC),
undergoing conservative approach. Noteworthy, a relevant
number of patients do not complete the planned treatment
interruption. Study aim was to analyze retrospectively the
reasons of treatment. Patients and Methods: Consecutive
patients affected by T1G3 BC, undergoing BCG maintenance
for one year, according to the SWOG schedule (3 weekly
instillations at 3, 6, 12 months) were included in this study.
Connaught BCG (81 mg/50 ml) was given starting 1430 days
after TUR. If toxicity occurred, treatment was postponed up
to two weeks. No dose reduction was considered. The
patients’ compliance with the treatment was analyzed. Results:
Out of 160 patients, 148 (92.5%) completed the induction
cycle. In 10 (6.3%) more patients a recurrence was detected.
In 15 (9.4%) patients induction only was planned due to
personal difficulties. In 123 patients (76.8%) maintenance for
one year was planned. However, 8 patients never started and 67 (54.4%) completed only one year maintenance: 6 (4.8%)
interrupted for toxicity and 9 (7,3%) for recurrence.
Compliance decreased from 84.5% at 3 to 57,7% at 12
months, 56 (45.6%) patients not completing one-year. In
particular 109 patients (83.8%) completed the maintenance at
3 and 88 (67.2%) at 6 months. Noteworthy, mild grade I BCG
toxicity, not requiring therapy on urologists’ opinion, was
recorded in 91 (74%) out of 123 patients in whom
maintenance was planned. Main limit was the retrospective
nature of the study. Conclusion: Maintenance interruption was
due to moderate-severe toxicity in only 5% of the patients.
The poor patient’s compliance was probably multifactorial,
partially related to grade I toxicity, not taken into appropriate
account by the urologists. A correct and periodical counselling
with the patients undergoing BCG maintenance regimen could
ameliorate the compliance to BCG
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica
To reduce the number of negative prostate biopsies in patients with elevated PSA serum levels represents a major challenge in urological oncology. Angiogenetic factors might be involved in initial stages of prostate cancer and might represent useful tools in patients' selection for prostate biopsy. The plasmatic levels of Angiopoietin-2, Follistatin, G-CSF, HGF, IL-8, Leptin, PDGF-BB, PECAM-1 and VEGF were measured by BioPlex immunoassay in patients undergoing prostate biopsy for palpable prostate nodule and/or elevated PSA levels ( 654 ng/mL). They were related with biopsy results. ROC curve analysis was exploited to test the diagnostic accuracy of each biomarker by AUC calculation. A potential cut-off level was computed. Fifty patients were entered. Median PSA was 6.8 ng/mL. A prostate nodule was palpable in 18 (36%) patients. The median number of biopsy cores was 12. Prostate cancer was detected in 25 (50%) and ASAP and PIN in 2 more patients (4%) respectively. Among the 9 considered biomarkers, only leptin showed an interesting diagnostic performance with an AUC of 0.781, at a cut-off value of 2.11 ng/mL, demonstrating a sensitivity of 78%, a specificity of 77% and a positive predictive value of 85%. Main limitations of our study are the exploratory design and the criteria adopted for patients' selection determining a detection rate for prostate cancer above the usual range. Leptin only, in our preliminary study, shows promising diagnostic accuracy for the selection of patients candidate to prostate biopsy. Further studies are required to confirm its diagnostic value and its relation with BMI